Plus   Neg

GTX Inc. (GTXI) Plummets After Phase 2 Study Fails

GTX Inc. (GTXI) announced Friday morning that its Phase 2 study of enobosarm failed to achieve its primary endpoint.

GTX has gapped open dramatically lower this morning and is now down 21.31 at $1.98 on the highest volume of the year. The stock has plunged to a new low for the year.

For comments and feedback contact: editorial@rttnews.com

Business News

Follow RTT